Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01873833
Title Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Southern California

Her2-receptor positive breast cancer


Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.